BBI-940 / Boundless Bio - LARVOL DELTA

BBI-940 novel Kinesin program targeting ecDNA segregation and inheritance (GlobeNewswire) - "The Company expects to submit an investigational new drug (IND) application for BBI-940 and initiate a first-in-human Phase 1 clinical trial in the first half of 2026; Initial proof-of-concept clinical data are expected within the Company’s existing cash runway timeline."

IND • New P1 trial • P1 data • Oncology

Boundless Bio Announces Portfolio Prioritization and Runway Extension (GlobeNewswire) - "Declared BBI-940 as the development candidate for novel Kinesin program; IND submission on track for the first half of 2026."

IND • Oncology

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) - "Boundless expects to nominate a development candidate for its preclinical program targeting a previously undrugged kinesin by mid-2025, with an investigational new drug (IND) submission planned for the first half of 2026."

IND • Pipeline update • Oncology

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire) - "We are on track to nominate a development candidate for our Kinesin program by mid-year, with the intention to submit an IND in the first half of 2026. We look forward to the year ahead as we continue to advance our pipeline to address the significant unmet need in patients with oncogene amplified cancers."

IND • Oncology